[A20-47] Solriamfetol (narcolepsy) - Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2020
Project no.:
A20-47
Commission:
Commission awarded on 18.05.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Improvement of wakefulness and reduction of excessive daytime sleepiness in adults with narcolepsy
Added benefit not proven for either of both research questions (patients with/without cataplexy).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.